RxDoctor Payments Data

Neha Rickson, MD

Endocrinology, Diabetes & Metabolism · Winter Garden, FLNPI 1568657732

Payments from drug & device makers

$8,135in general payments, 2019–2025

Across 192 payments — averaging $42.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tandem Diabetes Care, Inc.$5K
  • Novo Nordisk$347
  • Lilly USA, LLC$334
  • IBSA Pharma Inc.$228
  • AbbVie$226
  • Amgen$172
  • plus $2K from 32 others

What the payments were for

  • Speaking & faculty fees$4,70058%
  • Food & beverage$3,39842%
  • Education$370%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,135 in reported general payments places this provider in the 60th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

See all endocrinology, diabetes & metabolism providers in Florida

Medicare billing

Part B allowed, 2024
$93,908
Medicare patients
233
Services billed
1,327

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide247$279,047
OzempicSemaglutide100$121,475
JardianceEmpagliflozin87$100,807
JanuviaSitagliptin Phosphate64$54,157
TrulicityDulaglutide46$51,195
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog45$41,837
FarxigaDapagliflozin Propanediol40$32,882
RybelsusSemaglutide13$25,097
Tresiba Flextouch U-200Insulin Degludec23$22,870
Tresiba Flextouch U-100Insulin Degludec47$17,265
Fiasp FlextouchInsulin Aspart (Niacinamide)28$16,111
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog25$14,500
SynthroidLevothyroxine Sodium80$7,685
Hydrocortisone121$6,822
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$5,575

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog$334$332,783306 claims
Novo NordiskOzempic, Rybelsus$347$146,572113 claims
Boehringer IngelheimJardiance$23$100,80787 claims
MerckJanuvia$130$54,15764 claims
AstraZenecaFarxiga$171$32,88240 claims
AbbVieSynthroid$226$7,68580 claims
Amneal Pharmaceuticals LLCUnithroid, Levothyroxine Sodium$106$6,022373 claims
Sanofi-aventis U.S. LLCLantus$80$1,53112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

Other endocrinology, diabetes & metabolism in Winter Garden

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →